<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30695995</article-id>
<article-id pub-id-type="pmc">6387422</article-id>
<article-id pub-id-type="doi">10.3390/ijms20030535</article-id>
<article-id pub-id-type="publisher-id">ijms-20-00535</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effects of Resveratrol in the Treatment of Metabolic Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8007-6077</contrib-id>
<name>
<surname>Hou</surname>
<given-names>Chih-Yao</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-00535">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7059-6407</contrib-id>
<name>
<surname>Tain</surname>
<given-names>You-Lin</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-00535">2</xref>
<xref ref-type="aff" rid="af3-ijms-20-00535">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1242-8760</contrib-id>
<name>
<surname>Yu</surname>
<given-names>Hong-Ren</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-00535">2</xref>
<xref ref-type="aff" rid="af3-ijms-20-00535">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7403-288X</contrib-id>
<name>
<surname>Huang</surname>
<given-names>Li-Tung</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-00535">2</xref>
<xref ref-type="aff" rid="af4-ijms-20-00535">4</xref>
<xref ref-type="corresp" rid="c1-ijms-20-00535">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-00535"><label>1</label>Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung 811, Taiwan; <email>chihyaohou@gmail.com</email></aff>
<aff id="af2-ijms-20-00535"><label>2</label>Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; <email>tainyl@hotmail.com</email> (Y.-L.T.); <email>yuu2004taiwan@yahoo.com.tw</email> (H.-R.Y.)</aff>
<aff id="af3-ijms-20-00535"><label>3</label>Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan</aff>
<aff id="af4-ijms-20-00535"><label>4</label>Department of Traditional Medicine, Chang Gung University, Linkow 333, Taiwan</aff>
<author-notes>
<corresp id="c1-ijms-20-00535"><label>*</label>Correspondence: <email>litung.huang@gmail.com</email>; Tel.: +886-975056169; Fax: +886-7-7338009</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<elocation-id>535</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Resveratrol, also known as 3,5,4′-trihydroxystilbene, is a natural polyphenol that occurs as a phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, peanuts, and other oilseeds. This compound has a variety of effects on human health and diseases. This review summarizes the mounting evidence that resveratrol is helpful in treating metabolic syndrome and related disorders. Resveratrol can be provided either early as a reprogramming agent or later as part of treatment. A few of the main mechanisms underlying the beneficial effects of resveratrol on metabolic syndrome are outlined. This review also discusses the potential of resveratrol derivatives as a complementary or alternative medicine. In conclusion, resveratrol could be a useful regimen for the prevention and treatment of metabolic syndrome and its related conditions.</p>
</abstract>
<kwd-group>
<kwd>resveratrol</kwd>
<kwd>metabolic syndrome</kwd>
<kwd>high-fat diet</kwd>
<kwd>resveratrol derivatives</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-00535" sec-type="intro">
<title>1. Introduction</title>
<p>Resveratrol (<italic>trans</italic>-3,5,4′-trihydroxystilbene) is widely known as a phenolic compound from the stilbene family, with a C6–C2–C6 structure containing three hydroxyl groups and powerful antioxidant activity, which is found in various plants. In plants, resveratrol serves as an ultraviolet (UV) protectant and plays a role as a defense compound against pathogens infection, injury, and abiotic stresses [<xref ref-type="bibr" rid="B1-ijms-20-00535">1</xref>,<xref ref-type="bibr" rid="B2-ijms-20-00535">2</xref>]. It is present in over 70 types of plants, including grape skins, grape seeds, giant knotweed, cassia seeds, passion fruit, white tea, plums, and peanuts [<xref ref-type="bibr" rid="B2-ijms-20-00535">2</xref>,<xref ref-type="bibr" rid="B3-ijms-20-00535">3</xref>,<xref ref-type="bibr" rid="B4-ijms-20-00535">4</xref>,<xref ref-type="bibr" rid="B5-ijms-20-00535">5</xref>]. </p>
<p>Resveratrol was first isolated from the roots of the white hellebore (<italic>Veratrum grandiflorum</italic> O. Loes). In 1963, it was found in the roots of <italic>Polygonum cuspidatum</italic>. Initially characterized as a phytoalexin, resveratrol attracted little interest until 1992 [<xref ref-type="bibr" rid="B6-ijms-20-00535">6</xref>]. It has also been found in Japanese Knotweed [<xref ref-type="bibr" rid="B7-ijms-20-00535">7</xref>], grapevine tissue and barriers and in grapevine cell cultures under abiotic and biotic stresses [<xref ref-type="bibr" rid="B4-ijms-20-00535">4</xref>,<xref ref-type="bibr" rid="B6-ijms-20-00535">6</xref>]. Due to resveratrol’s utility, a sustainable source of resveratrol is required. Currently, the majority of commercial resveratrol is extracted from <italic>Polygonum cuspidatum</italic> [<xref ref-type="bibr" rid="B3-ijms-20-00535">3</xref>], leading to a variety of compositions and purities. The requirement for lower cost and high purity resveratrol has promoted its heterologous biosynthesis in engineered microbes. The first study on the quantitative production of resveratrol was in <italic>Saccharomyces cerevisiae</italic> based on feeding ρ-coumaric acid and the expression of two heterologous enzymes 4-coumaryl-CoA ligase (4CL) and resveratrol synthase (VST1, also called stilbene synthase, STS) [<xref ref-type="bibr" rid="B3-ijms-20-00535">3</xref>,<xref ref-type="bibr" rid="B8-ijms-20-00535">8</xref>]. </p>
<p>Resveratrol has been used in medicines, dietary supplements and as a functional food ingredient; positive effects of resveratrol on health have also been confirmed in several studies. It has preventive effects on oxidation, inflammation, cardiovascular disease and has anticarcinogenic activity, among other health benefits [<xref ref-type="bibr" rid="B5-ijms-20-00535">5</xref>,<xref ref-type="bibr" rid="B9-ijms-20-00535">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-00535">10</xref>,<xref ref-type="bibr" rid="B11-ijms-20-00535">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-00535">12</xref>]. </p>
</sec>
<sec id="sec2-ijms-20-00535">
<title>2. The Synthesis and Functions of Resveratrol</title>
<p>A review of literature has shown that resveratrol is synthesized by plants as a response to unfavorable or stressful conditions, damage, and mechanical injury. In the physiological metabolism of plants, glucose is metabolized to 4-coumaroyl-CoA and is combined with malonyl-CoA via stilbene synthase to produce trans-resveratrol (<xref ref-type="fig" rid="ijms-20-00535-f001">Figure 1</xref>). In response to bacteria or fungi or UV exposure, two forms of resveratrol can be produced, namely trans- and cis-isomers. In addition, while trans-resveratrol occurs naturally in grapes, various technologies have identified cis-resveratrol and its glucoside in wines of diverse origin. It was detected that the vinification process transforms some <italic>trans</italic>-resveratrol into its <italic>cis</italic>-form. Nevertheless, when protected from light, the <italic>trans</italic>-form can be stable for months, except in high pH, while cis-resveratrol was stable only in neutral pH [<xref ref-type="bibr" rid="B13-ijms-20-00535">13</xref>]. In addition, resveratrol has been demonstrated to be a natural antimicrobial agent [<xref ref-type="bibr" rid="B14-ijms-20-00535">14</xref>]. It also modulates gut microbiota composition and hence has anti-diabetic, anti-obesity, and anti-atherosclerosis properties [<xref ref-type="bibr" rid="B15-ijms-20-00535">15</xref>].</p>
<p>Resveratrol is most known for its purported health benefits (e.g., heart health-related claims about the resveratrol present in red wine). Sources of resveratrol include Japanese knotweed, red grape varieties and other berries, but it can also be produced synthetically and by fermentation. A proposed monograph on trans-resveratrol produced by yeast fermentation represents the first proposed authoritative standard for resveratrol as a food ingredient. No obvious resveratrol toxicity has been noted in humans [<xref ref-type="bibr" rid="B16-ijms-20-00535">16</xref>]; however, <italic>trans</italic>-resveratrol at a dose of 2000 mg twice daily caused diarrhea and clinically irrelevant changes of serum potassium and total bilirubin levels in healthy subjects [<xref ref-type="bibr" rid="B17-ijms-20-00535">17</xref>].</p>
</sec>
<sec id="sec3-ijms-20-00535">
<title>3. Metabolic Syndrome</title>
<p>Metabolic syndrome is a cluster of metabolic disorders. The condition includes hypertension, high blood sugar or diabetes mellitus, obesity, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, patients presenting with several of these conditions have a greater chance for future cardiovascular events than those with any one factor alone. Metabolic syndrome is a growing problem globally and is a contributor to non-communicable diseases such as type II diabetes, cardiovascular disease, and cognitive deficits. A large body of epidemiologic literature supports an inverse relationship between birth weight and both systolic blood pressure and hypertension. In addition, hypertension can originate from early-life insults, referred to as the “developmental origins of health and disease (DOHaD)’’, by Gluckman et al., who proposed the concept of DOHaD after observing the enduring effects of the fetal environment on physical health and disease in adulthood [<xref ref-type="bibr" rid="B18-ijms-20-00535">18</xref>]. The process of fetal programming or developmental plasticity is one of the core assumptions of DOHaD [<xref ref-type="bibr" rid="B19-ijms-20-00535">19</xref>]. Metabolic syndrome is now considered a disease of developmental origin [<xref ref-type="bibr" rid="B18-ijms-20-00535">18</xref>], which has become a main priority of recent research.</p>
</sec>
<sec id="sec4-ijms-20-00535">
<title>4. Mechanisms of Resveratrol Action in the Treatment of Metabolic Syndrome</title>
<p>Resveratrol acts through different mechanisms to improve the symptoms of metabolic syndrome and related disorders [<xref ref-type="bibr" rid="B20-ijms-20-00535">20</xref>]. Below, we summarize a few of the main targets of resveratrol in healthy and disease states.</p>
<sec id="sec4dot1-ijms-20-00535">
<title>4.1. SIRT1</title>
<p>The sirtuin family of proteins catalyzes the Nicotinamide adenine dinucleotide (NAD<sup>+</sup>)-dependent deacylation of acyl-lysine residues. Changes in sirtuin expression are critical in several diseases, including metabolic syndrome, cardiovascular diseases, cancer, and neurodegeneration. Increasing levels of the SIRT1 protein help control some disease related conditions including obesity, cardiovascular diseases and neurodegeneration [<xref ref-type="bibr" rid="B21-ijms-20-00535">21</xref>]. Resveratrol activates Sirtuins (SIRT)1, which has a variety of biological and pharmacological effects, including cardio protective, antioxidant, and anti-inflammatory effects [<xref ref-type="bibr" rid="B22-ijms-20-00535">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-00535">23</xref>]. SIRT1 transgenic mice display some features resembling calorie restriction.</p>
</sec>
<sec id="sec4dot2-ijms-20-00535">
<title>4.2. AMPK</title>
<p>AMP-activated protein kinase (AMPK) is a protein kinase that maintains homeostasis in cells and organs. Interestingly, the health benefits of SIRT1 activation following resveratrol overlap in many ways with those conferred by AMPK activation. AMPK has emerged as a key nutrient sensor, with the ability to regulate whole-body metabolism [<xref ref-type="bibr" rid="B24-ijms-20-00535">24</xref>], coordinating many metabolic reactions [<xref ref-type="bibr" rid="B25-ijms-20-00535">25</xref>] to maintain metabolic homeostasis and induce the inflammatory response [<xref ref-type="bibr" rid="B26-ijms-20-00535">26</xref>]. Tamaki et al. reported that resveratrol has the ability to activate SIRT1, AMPK, and Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/antioxidant defense pathways in a rat periodontitis model [<xref ref-type="bibr" rid="B27-ijms-20-00535">27</xref>]. </p>
</sec>
<sec id="sec4dot3-ijms-20-00535">
<title>4.3. Renin-Angiotensin System</title>
<p>RAS plays an important role in metabolic syndrome [<xref ref-type="bibr" rid="B28-ijms-20-00535">28</xref>]. In Ang II-stimulated vascular smooth muscle cells (VSMCs), resveratrol treatment markedly decreased the number of senescence associated β-galactosidase stained cells and pro-fibrotic protein expression and increased the expression of AT2R and MasR [<xref ref-type="bibr" rid="B29-ijms-20-00535">29</xref>]. </p>
</sec>
<sec id="sec4dot4-ijms-20-00535">
<title>4.4. Others</title>
<p>Recently, an important feature of resveratrol has been documented. Resveratrol may affect gut microbiota and their metabolic products, such as short chain fatty acids and intraluminal lipids, and hence alleviate metabolic syndrome [<xref ref-type="bibr" rid="B15-ijms-20-00535">15</xref>,<xref ref-type="bibr" rid="B30-ijms-20-00535">30</xref>]. Resveratrol also modulates mitochondrial function and dynamics and may induce the regulation of transcription factors that activate or repress the expression of mitochondria-related genes, causing alterations in the mitochondrial physiology [<xref ref-type="bibr" rid="B31-ijms-20-00535">31</xref>]. A wide range of SIRT1 substrates have already been described, including key regulators of mitochondrial respiration, lipid metabolism and aging processes, such as the Forkhead box class O (FOXO) family of transcription factors [<xref ref-type="bibr" rid="B32-ijms-20-00535">32</xref>]. In addition to its activation of SIRT1, resveratrol is presumably involved in transcriptional regulation of the nuclear factor kappa-B cells (NF-κB) family of proteins. Nrf2-Keap1 signaling also has been reported in diabetic nephropathy in response to resveratrol [<xref ref-type="bibr" rid="B33-ijms-20-00535">33</xref>]. Anti-inflammation is also one of the major mechanisms of action by which resveratrol acts on metabolic syndrome [<xref ref-type="bibr" rid="B34-ijms-20-00535">34</xref>].</p>
</sec>
</sec>
<sec id="sec5-ijms-20-00535">
<title>5. Treatment of Metabolic Syndrome</title>
<p>The treatment of metabolic syndrome consists of mainly life style changes and pharmacological approaches. Since metabolic syndrome is now considered to have a developmental origin, the first approach should be reprogramming [<xref ref-type="bibr" rid="B18-ijms-20-00535">18</xref>]. Later in life, resveratrol intervention can be considered as a therapeutic supplement [<xref ref-type="bibr" rid="B35-ijms-20-00535">35</xref>]. <xref ref-type="fig" rid="ijms-20-00535-f002">Figure 2</xref> outlines the possible underlying mechanisms of resveratrol effects on metabolic syndrome and therapeutic strategies including early-life reprogramming and later-life intervention.</p>
<sec id="sec5dot1-ijms-20-00535">
<title>5.1. Reprogramming of Metabolic Syndrome by Resveratrol</title>
<p>Metabolic syndrome is defined as central obesity plus any two of the following factors: elevated triglycerides, reduced High-density lipoproteins (HDL) cholesterol, elevated blood pressure or blood glucose abnormalities [<xref ref-type="bibr" rid="B36-ijms-20-00535">36</xref>]. Metabolic syndrome is now considered a disease of developmental origin [<xref ref-type="bibr" rid="B18-ijms-20-00535">18</xref>]. Developmental programming, also known as DOHaD [<xref ref-type="bibr" rid="B37-ijms-20-00535">37</xref>], refers to exposure during prenatal or early postnatal development that may cause permanent changes in an individual’s physiology and metabolism that predispose them to non-communicable diseases, such as Alzheimer’s, asthma, chronic kidney disease, and diabetes mellitus [<xref ref-type="bibr" rid="B38-ijms-20-00535">38</xref>]. Reprogramming offers an opportunity, in the critical period of early development, to reverse this predisposition [<xref ref-type="bibr" rid="B39-ijms-20-00535">39</xref>,<xref ref-type="bibr" rid="B40-ijms-20-00535">40</xref>]. Tain et al. have previously reported on the potential role of melatonin in reprogramming metabolic syndrome following early perinatal insults. Reprogramming metabolic syndrome following early perinatal insults by resveratrol has also been reported. Signaling during reprogramming include SIRT1, Nrf2, and AMPK, all of which can be adjusted by resveratrol [<xref ref-type="bibr" rid="B23-ijms-20-00535">23</xref>,<xref ref-type="bibr" rid="B27-ijms-20-00535">27</xref>,<xref ref-type="bibr" rid="B41-ijms-20-00535">41</xref>]. We therefore in this review article discuss the role of resveratrol in the treatment of metabolic syndrome. </p>
<p>The effective treatment of metabolic syndrome has been less convincing in human studies than in animal studies [<xref ref-type="bibr" rid="B42-ijms-20-00535">42</xref>]. We will first discuss human studies, followed by preclinical studies on the effects of resveratrol in metabolic syndrome.</p>
</sec>
<sec id="sec5dot2-ijms-20-00535">
<title>5.2. Treatment of Metabolic Syndrome by Resveratrol</title>
<sec id="sec5dot2dot1-ijms-20-00535">
<title>5.2.1. Clinical Studies</title>
<p>Resveratrol is being tested in many clinical trials, as it may exert these effects by targeting several main metabolic sensor/effector proteins, such as AMPK, SIRT1, and Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) [<xref ref-type="bibr" rid="B43-ijms-20-00535">43</xref>]. A randomized, double-blind, placebo-controlled clinical trial in 24 patients with diagnoses of metabolic syndrome showed that resveratrol significantly decreases weight, Body Mass Index (BMI), fat mass, waist circumference, area under curve of insulin, and total insulin secretion [<xref ref-type="bibr" rid="B44-ijms-20-00535">44</xref>]. In a randomized, four-month study of middle-aged men with metabolic syndrome, Korsholm and colleagues found that resveratrol treatment reduced sulfated androgen precursors in blood, adipose tissue, and muscle tissue, and increased these metabolites in urine [<xref ref-type="bibr" rid="B45-ijms-20-00535">45</xref>]. They also found increased intracellular glycerol and an accumulation of long-chain saturated, monounsaturated, and polyunsaturated free fatty acids in the muscle of resveratrol-treated men. In addition, changes in urinary derivatives of aromatic amino acids, suggested an altered gut microbiota composition following resveratrol treatment. They concluded that there was evidence that resveratrol has subtle but robust effects on several metabolic pathways in men with metabolic syndrome. They stress that the effects would not have been detected by routine analyses. Amiot et al. reviewed the clinical evidence of chronic food or nutrient supplements in patients with metabolic syndrome, concluding that diets rich in polyphenols, for example the Mediterranean diet, could be an effective nutritional strategy [<xref ref-type="bibr" rid="B46-ijms-20-00535">46</xref>]. Recently, a meta-analysis investigating inflammatory markers among patients with metabolic syndrome and related disorders showed that resveratrol supplementation significantly decreased C-reactive protein and tumor necrosis factor-α concentrations, while there was no significant change in Interleukin 6 and superoxide dismutase concentrations [<xref ref-type="bibr" rid="B47-ijms-20-00535">47</xref>]. They concluded that resveratrol supplementation showed a promising effect on lowering some inflammatory markers among patients with metabolic syndrome and related disorders [<xref ref-type="bibr" rid="B48-ijms-20-00535">48</xref>]. Longevinex, a modified resveratrol, improved endothelial function in patients with metabolic syndrome [<xref ref-type="bibr" rid="B49-ijms-20-00535">49</xref>]. Longevinex specifically improved endothelial function in 34 patients with metabolic syndrome who were receiving standard therapy for lifestyle-related diseases [<xref ref-type="bibr" rid="B49-ijms-20-00535">49</xref>]. In contrast, 1000 or 150 mg daily resveratrol in middle-aged, community-dwelling men with metabolic syndrome showed negative results [<xref ref-type="bibr" rid="B50-ijms-20-00535">50</xref>]. Resveratrol treatment did not improve their inflammatory status, glucose homeostasis, blood pressure, or hepatic lipid content. However, resveratrol significantly increased total cholesterol, LDL cholesterol, and fructosamine levels compared with controls [<xref ref-type="bibr" rid="B50-ijms-20-00535">50</xref>]. Collectively, the results of clinical studies are unsatisfactory and varied due to different study designs, resveratrol dosages, and treatment durations, or low bioavailability of the supplement [<xref ref-type="bibr" rid="B51-ijms-20-00535">51</xref>]. </p>
</sec>
<sec id="sec5dot2dot2-ijms-20-00535">
<title>5.2.2. Preclinical Studies</title>
<p>● Brain</p>
<p>Resveratrol might alter gut microbiome, affect the gut-brain axis, and have a role in brain disorders [<xref ref-type="bibr" rid="B15-ijms-20-00535">15</xref>,<xref ref-type="bibr" rid="B30-ijms-20-00535">30</xref>,<xref ref-type="bibr" rid="B52-ijms-20-00535">52</xref>]. Aquaporins are integral, transmembrane, water channel proteins that are now implicated in metabolic syndrome [<xref ref-type="bibr" rid="B51-ijms-20-00535">51</xref>]. Resveratrol also exerts beneficial effects by modulating brain aquaporins and exert beneficial effects [<xref ref-type="bibr" rid="B53-ijms-20-00535">53</xref>]. Evidence suggests that resveratrol may augment brain-derived neurotrophic factor (BDNF) synthesis, which can prevent bisphenol-A-induced autism, metabolic syndrome, and diabetes mellitus [<xref ref-type="bibr" rid="B23-ijms-20-00535">23</xref>]. People with metabolic syndrome are more likely to experience cognitive dysfunction as obesity is an independent risk factor for the development of cognitive decline in both the middle-aged and elderly [<xref ref-type="bibr" rid="B48-ijms-20-00535">48</xref>,<xref ref-type="bibr" rid="B54-ijms-20-00535">54</xref>]. Resveratrol might also be beneficial for the prevention of diabetes-related cognitive impairment [<xref ref-type="bibr" rid="B55-ijms-20-00535">55</xref>]. In streptozotocin-injected diabetic rats, resveratrol administration for four weeks improved hippocampus-dependent cognitive deficit. Heyward et al. showed that mice maintained on a high-fat diet develop impaired hippocampus-dependent spatial memory possibly mediated by the epigenetic dysregulation of SIRT1 within the hippocampus [<xref ref-type="bibr" rid="B56-ijms-20-00535">56</xref>]. Resveratrol also reversed changes to caspase-3, Bax, Bcl-2, <italic>N</italic>-Methyl-<sc>d</sc>-Aspartate (NMDA) receptor, and brain derived neurotrophic factor activity in the hippocampus [<xref ref-type="bibr" rid="B57-ijms-20-00535">57</xref>].</p>
<p>Our research group found that a combined maternal and postnatal high-fat diet caused metabolic syndrome and cognitive dysfunction in adult rat offspring [<xref ref-type="bibr" rid="B58-ijms-20-00535">58</xref>]. We observed lower expression of dorsal hippocampal BDNF in maternal and postnatal high-fat diet rats, which was reversed by resveratrol therapy, as was the associated cognitive dysfunction [<xref ref-type="bibr" rid="B58-ijms-20-00535">58</xref>]. Rats with diet-induced metabolic syndrome also had less dorsal hippocampal SIRT1, which resveratrol was also able to restore [<xref ref-type="bibr" rid="B59-ijms-20-00535">59</xref>]. Our research also found lower dorsal hippocampal AT1R expressions in diet induced metabolic syndrome rats, which again was restored by resveratrol treatment [<xref ref-type="bibr" rid="B59-ijms-20-00535">59</xref>]. These findings suggest that resveratrol could reverse cognitive dysfunction through modulating dorsal hippocampal BDNF, SIRT1, and AT1R in rats with metabolic syndrome. </p>
<p>● Liver</p>
<p>Lipid metabolism disorders are an important predisposing factor for fatty liver disease pathogenesis, which is characterized by excessive lipid accumulation in the liver [<xref ref-type="bibr" rid="B60-ijms-20-00535">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-00535">61</xref>]. SIRT1 is the most extensively studied protein implicated in lipid metabolism disorders, and plays a role in both alcoholic and nonalcoholic fatty liver disease (NAFLD) [<xref ref-type="bibr" rid="B41-ijms-20-00535">41</xref>]. SIRT1 plays multiple roles including regulating hepatic lipid metabolism, controlling hepatic oxidative stress, and inhibiting hepatic inflammation through deacetylating transcriptional regulators that promote the progression of fatty liver disease. SIRT1 could protect against a high-fat diet or alcohol-induced hepatic steatosis via various metabolic pathways [<xref ref-type="bibr" rid="B41-ijms-20-00535">41</xref>,<xref ref-type="bibr" rid="B62-ijms-20-00535">62</xref>,<xref ref-type="bibr" rid="B63-ijms-20-00535">63</xref>]. In rats, <italic>N</italic>′-Nitrosodimethylamine-induced liver fibrosis was alleviated by resveratrol. Resveratrol was able to revert the liver damages by increasing histological integrity, repressing oxidative damage and inhibiting liver stellate cells activation by down regulating α-Smooth muscle actin expression [<xref ref-type="bibr" rid="B64-ijms-20-00535">64</xref>]. A study of the effects of resveratrol treatment on hepatic oxidative stress in a rat model of metabolic syndrome induced by high fructose diet showed that resveratrol therapy had beneficial effects on liver paraoxonase activity [<xref ref-type="bibr" rid="B65-ijms-20-00535">65</xref>]. Similarly, resveratrol showed beneficial effects on hepatic oxidative stress in a rat model of fructose diet-induced metabolic syndrome [<xref ref-type="bibr" rid="B66-ijms-20-00535">66</xref>]. Burgess et al. tested resveratrol in pigs with high calorie and high-fat/cholesterol-induced metabolic syndrome [<xref ref-type="bibr" rid="B67-ijms-20-00535">67</xref>]. They found that supplemental resveratrol positively influenced glucose metabolism pathways in the liver and skeletal muscle and led to improved glucose control.</p>
<p>Studies from our group demonstrated mRNA levels of angiotensinogen, renin, ACE1, and AT1R in the liver were increased in rats exposed to a combined maternal and postnatal high-fat diet, which were significantly decreased following resveratrol therapy. In addition, histopathology showed that resveratrol therapy also decreased lipid droplets, MDA levels, and leptin receptors in the liver of rats with diet induced metabolic syndrome [<xref ref-type="bibr" rid="B68-ijms-20-00535">68</xref>]. These findings suggest that resveratrol therapy might play a beneficial role in the liver in rats with metabolic syndrome via renin-angiotensin system modulation [<xref ref-type="bibr" rid="B68-ijms-20-00535">68</xref>].</p>
<p>● Kidney</p>
<p>Diabetic nephropathy is a common complication of metabolic syndrome. Kim et al. showed that resveratrol prevents diabetic nephropathy in db/db mice through the phosphorylation of AMPK and activation of SIRT1-PGC-1α signaling, which appears to prevent lipotoxicity-related apoptosis and oxidative stress in the kidney [<xref ref-type="bibr" rid="B69-ijms-20-00535">69</xref>].</p>
<p>Emerging evidence suggests an active role for the renin-angiotensin system (RAS) in the development of hypertension. Our research group found that a combination of a maternal and a postnatal high-fat diet increased the level of Ang I and reduced the level of Ang (1–7) in plasma, resveratrol treatment therapy significant reduced plasma Ang II levels and increased AMPK2α phosphorylation [<xref ref-type="bibr" rid="B62-ijms-20-00535">62</xref>] and prevented Ang II induced-hypertension via AMPK activation [<xref ref-type="bibr" rid="B62-ijms-20-00535">62</xref>,<xref ref-type="bibr" rid="B70-ijms-20-00535">70</xref>]. In addition, the combination of a maternal and a postnatal high-fat diet decreased mRNA expression of Ulk1 and Atg5. Resveratrol treatment prevented the decreases in Ulk1 and Atg5 mRNA levels as well as increasing the LC3-II/LC3-I ratio [<xref ref-type="bibr" rid="B62-ijms-20-00535">62</xref>]. These results indicate that a combined maternal and post-weaning high-fat diet can inhibit autophagy, which was rescued by resveratrol. The above findings suggest that resveratrol could reverse nephropathy and hypertension in rats with metabolic syndrome through the regulation of RAS, oxidative stress, autophagy, and nutrient-sensing signals.</p>
<p>● Adipose tissue</p>
<p>Excessive accumulation and persistence of low-grade inflammation in adipose tissue are typical features of obesity. Adipose tissue is recognized as a metabolically active organ and is involved in producing many adipokines to modulate target organs [<xref ref-type="bibr" rid="B71-ijms-20-00535">71</xref>]. For example, leptin plays an important role in metabolic regulation, energy expenditure, and glucose homeostasis. The presence of high concentrations of leptin accompanied with down-regulation of the hypothalamic leptin receptors and dysfunction in leptin signaling together comprise “leptin resistance” in obesity [<xref ref-type="bibr" rid="B72-ijms-20-00535">72</xref>]. Resveratrol treatment can decrease blood leptin concentrations [<xref ref-type="bibr" rid="B73-ijms-20-00535">73</xref>] and seems to ameliorate leptin resistance. Adipose tissues store triglycerides and release fatty acids through lipogenesis and lipolysis, respectively. Resveratrol treatment has been demonstrated to decrease lipogenesis and increase lipolysis, thus having an anti-obesity effect [<xref ref-type="bibr" rid="B74-ijms-20-00535">74</xref>]. It has also been shown to increases the capacity of thermogenesis in brown adipose tissue [<xref ref-type="bibr" rid="B75-ijms-20-00535">75</xref>]. Resveratrol is stronger inhibitor of PAI-1 expression than PI3K, Sirt1, AMPK, ROS, and Nrf2, through NF-κB modulation in inflamed adipose tissue [<xref ref-type="bibr" rid="B76-ijms-20-00535">76</xref>]. An in vitro study also showed that resveratrol treatment inhibited preadipocyte proliferation, adipogenic differentiation and inflammatory cytokines production in a Sirt1-dependent manner [<xref ref-type="bibr" rid="B77-ijms-20-00535">77</xref>]. Other beneficial effects of resveratrol treatment on adipocytes include improving insulin signaling and mitochondrial dynamics [<xref ref-type="bibr" rid="B78-ijms-20-00535">78</xref>,<xref ref-type="bibr" rid="B79-ijms-20-00535">79</xref>]. Resveratrol plus quercetin upregulated white adipose tissue SIRT1 and SIRT2 in a rat model of sucrose diet-induced metabolic syndrome [<xref ref-type="bibr" rid="B80-ijms-20-00535">80</xref>]. Recently it has been thought that the antiobesity effect of resveratrol is due to alteration in the gut microbiome and its related consequences [<xref ref-type="bibr" rid="B81-ijms-20-00535">81</xref>]. It is also proposed that altered microbiome might promote brown adipose tissue activation and white adipose tissue browning [<xref ref-type="bibr" rid="B82-ijms-20-00535">82</xref>].</p>
<p>We and colleagues also found that resveratrol can improve several dysregulated RAS molecules of visceral adipose tissue that resulted from prenatal and postnasal high-fat diet [<xref ref-type="bibr" rid="B59-ijms-20-00535">59</xref>]. Since RAS of adipose tissue has profound systemic effects [<xref ref-type="bibr" rid="B83-ijms-20-00535">83</xref>], resveratrol treatment has modulatory effects on the cardiovascular system through adipose tissue. The above findings suggest that resveratrol could affect adipose tissue and has beneficial effects in rats with metabolic syndrome. </p>
<p>Obesity results in chronic inflammation in adipose tissue, and that cells of the innate immune system, particularly macrophages, are crucially involved in adipose inflammation [<xref ref-type="bibr" rid="B84-ijms-20-00535">84</xref>]. Macrophages are subdivided into M1 and M2 in general. M1 macrophages are characterized by the production of pro-inflammatory cytokines, while M2 is anti-inflammatory macrophages that involved in the resolution of the inflammatory process and tissue repairing. The previous study has shown that resveratrol exerts anti-inflammatory effects by suppressing M1 microglia activation and promotes microglia polarization toward M2 phenotype via PGC-1α in conditions of neuroinflammatory injury [<xref ref-type="bibr" rid="B85-ijms-20-00535">85</xref>]. While the role of resveratrol for macrophage polarization seems controversial for adipose tissue. Resveratrol has been shown to attenuate hypoxia-induced macrophage migration to visceral white adipose tissue [<xref ref-type="bibr" rid="B86-ijms-20-00535">86</xref>]. However, resveratrol supplementation fails to improve obesity-induced macrophage infiltration and switching [<xref ref-type="bibr" rid="B87-ijms-20-00535">87</xref>]. Thus, the effect of resveratrol on macrophage polarization in adipose tissue may be mechanism-dependent. </p>
<p>● Pancreas and insulin sensitivity</p>
<p>Insulin resistance is a main feature of metabolic syndrome, and one for which resveratrol is especially effective. When Chen et al. treated insulin-resistant KKA(y) mice with 2 and 4 g/kg diets of resveratrol for 12 weeks [<xref ref-type="bibr" rid="B88-ijms-20-00535">88</xref>], they found that resveratrol intervention reduced blood glucose and serum insulin levels, improved insulin and glucose tolerance, and increased serum adiponectin. They concluded that resveratrol could improve insulin sensitivity and ameliorate insulin resistance in KKA(y) mice [<xref ref-type="bibr" rid="B88-ijms-20-00535">88</xref>]. Lagouge et al. investigated mice on a high-fat diet with or without resveratrol supplementation for 15 weeks. They found a significant reduction in fasting insulin levels in the resveratrol-treated rats compared with rats without resveratrol supplementation. This decrease in insulin was not accompanied by alterations in fasting glucose levels and was accompanied by improved insulin sensitivity [<xref ref-type="bibr" rid="B89-ijms-20-00535">89</xref>].</p>
<p>Our research group previously reported that resveratrol could reverse the increased sugar area under curve and insulin area under curve in rats exposed to a combined maternal and postnatal high-fat diet, through increased levels of SIRT1 mRNA and expression in the pancreas. In addition, resveratrol could reduce ACE in rats exposed to a combined maternal and postnatal high-fat diet [<xref ref-type="bibr" rid="B59-ijms-20-00535">59</xref>]. Moreover, the higher levels of plasma angiotensin II, indicating insulin resistance, seen in rats exposed to a combined maternal and postnatal high-fat diet was reversed by resveratrol treatment. The above findings suggest that resveratrol could reduce insulin resistance in rats with metabolic syndrome, in part through RAS regulation.</p>
<p><xref ref-type="table" rid="ijms-20-00535-t001">Table 1</xref> summarizes main clinical and pre-clinical studies of resveratrol on metabolic syndrome.</p>
</sec>
</sec>
</sec>
<sec id="sec6-ijms-20-00535">
<title>6. Resveratrol Derivatives</title>
<p>Despite the therapeutic effects of resveratrol, its experimental application has limited application due to its poor solubility and low bioavailability. Recent studies have been aimed at designing novel resveratrol formulations to overcome its poor solubility. Encapsulation of resveratrol into nanodevices has been explored. Resveratrol cross-linked chitosan nanoparticles modified with phospholipids (RVC-lipid) were synthesized using a double emulsion technique, to produce an amorphous structure, with a mean particle size of 950 nm in ethanol, and an encapsulation efficiency of 63.82% in an aqueous medium and 85.59% in an ethanol medium. However, based on assays of antioxidant activity, the scavenging activity of RVC-lipid nanoparticles was inferior to that of resveratrol due to its prolonged release [<xref ref-type="bibr" rid="B91-ijms-20-00535">91</xref>]. Elongation of the conjugated chain of resveratrol has proved to be an effective strategy to further improve its antioxidative capacity and radical scavenging ability. In addition, stable s-cis conformers of long chain resveratrol analogs are more favorable for the production of phenoxyl radicals and cation radicals than trans conformers, with concomitant enhancement in antioxidative activity [<xref ref-type="bibr" rid="B92-ijms-20-00535">92</xref>]. Oh et al. reported on twelve resveratrol derivatives prepared using acyl chlorides of different chain lengths (C3:0–C22:6) and found that the resveratrol showed the highest antioxidant activity in oil-in water emulsion, while its derivatives (RC6:0, RC8:0, RC10:0, RC12:0, RC16:0) showed better antioxidant activity in a bulk oil system. On the other hand, resveratrol esters RC20:5n-3 (REPA) and RC22:6n-3 (RDHA) had the highest antioxidant activity when added to ground meat [<xref ref-type="bibr" rid="B9-ijms-20-00535">9</xref>]. These results indicate that esterification had more antioxidant activity in the oil system and also demonstrated that the effect of esterification position, number of esterification substitution and the effect on bioactivity of esterification is still unclear and worth future investigation.</p>
</sec>
<sec id="sec7-ijms-20-00535" sec-type="conclusions">
<title>7. Conclusions</title>
<p>An enormous amount of clinical and animal studies on resveratrol suggests that it may improve health, prevent, and/or treat chronic diseases, such as metabolic syndrome. Given that life style modifications are difficult for the general population to adopt, resveratrol is worth exploring through more clinical and experimental studies. However, the effective treatment of metabolic syndrome has been less convincing in humans than in animal studies. Further studies are needed to understand the genetic factors that account for the differences in bioavailability and physiological responses to resveratrol among individuals. Moreover, it is important to develop different resveratrol derivatives in future studies. </p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This work was supported by Grant CMRPG8G0632 from Chang Gung Memorial Hospital, Kaohsiung, Taiwan to L.-T.H.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AMPK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">AMP-activated protein kinase </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AT1R</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Angiotensin II Type I Receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AT2R</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Angiotensin type 2 receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Bax</td>
<td align="left" colspan="1" rowspan="1" valign="middle">BCL2 Associated X, Apoptosis Regulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Bcl-2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">B-cell lymphoma 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BDNF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">brain-derived neurotrophic factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BMI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Body Mass Index</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DOHaD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Developmental origins of health and disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FOXO</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Forkhead box class O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MasR</td>
<td align="left" colspan="1" rowspan="1" valign="middle">receptor Mas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MKRN1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Makorin ring finger protein 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NAFLD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">nonalcoholic fatty liver disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NMDA receptor</td>
<td align="left" colspan="1" rowspan="1" valign="middle"><italic>N</italic>-Methyl-<sc>d</sc>-Aspartate receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Nrf2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nuclear factor (erythroid-derived 2)-like 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PAI-1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">plasminogen activator inhibitor-1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PGC-1α</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Peroxisome proliferator-activated receptor gamma coactivator-1α</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">RAS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Renin-angiotensin system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SIRT1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sirtuins 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">VSMCs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">vascular smooth muscle cells</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-00535">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frémont</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Biological effects of resveratrol</article-title>
<source/>Life Sci.
          <year>2000</year>
<volume>66</volume>
<fpage>663</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.1016/S0024-3205(99)00410-5</pub-id>
<pub-id pub-id-type="pmid">10680575</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-00535">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piotrowska</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kucinska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Murias</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Biological activity of piceatannol: Leaving the shadow of resveratrol</article-title>
<source/>Mutat. Res. /Rev. Mutat. Res.
          <year>2012</year>
<volume>750</volume>
<fpage>60</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.mrrev.2011.11.001</pub-id>
<pub-id pub-id-type="pmid">22108298</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-00535">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mei</surname>
<given-names>Y.Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Biocatalysis and biotransformation of resveratrol in microorganisms</article-title>
<source/>Biotechnol. Lett.
          <year>2015</year>
<volume>37</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1007/s10529-014-1651-x</pub-id>
<pub-id pub-id-type="pmid">25179823</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-00535">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Profiling influences of gene overexpression on heterologous resveratrol production in Saccharomyces cerevisiae</article-title>
<source/>Front. Chem. Sci. Eng.
          <year>2017</year>
<volume>11</volume>
<fpage>117</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1007/s11705-016-1601-3</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-00535">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chastang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pozzobon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Taidi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Courot</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Clément</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pareau</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Resveratrol production by grapevine cells in fed-batch bioreactor: Experiments and modelling</article-title>
<source/>Biochem. Eng. J.
          <year>2018</year>
<volume>131</volume>
<fpage>9</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.bej.2017.12.009</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-00535">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baur</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Therapeutic potential of resveratrol: The in vivo evidence</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2006</year>
<volume>5</volume>
<fpage>493</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="doi">10.1038/nrd2060</pub-id>
<pub-id pub-id-type="pmid">16732220</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-00535">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nonomura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kanagawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Makimoto</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of KO-J O-KON. (Polygonum Cuspidatum Sieb. ET ZUCC.)</article-title>
<source/>Yakugaku Zasshi J. Pharm. Soc. Jpn.
          <year>1963</year>
<volume>83</volume>
<fpage>988</fpage>
<lpage>990</lpage>
<pub-id pub-id-type="doi">10.1248/yakushi1947.83.10_988</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-00535">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vandermerwe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lambrechts</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vivier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pretorius</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Metabolic engineering of for the synthesis of the wine-related antioxidant resveratrol</article-title>
<source/>FEMS Yeast Res.
          <year>2003</year>
<volume>4</volume>
<fpage>79</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/S1567-1356(03)00157-0</pub-id>
<pub-id pub-id-type="pmid">14554199</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-00535">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Shahidi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Antioxidant activity of resveratrol ester derivatives in food and biological model systems</article-title>
<source/>Food Chem.
          <year>2018</year>
<volume>261</volume>
<fpage>267</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.foodchem.2018.03.085</pub-id>
<pub-id pub-id-type="pmid">29739593</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-00535">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donnelly</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Fenwick</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>R.H.F.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>R.E.K.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms</article-title>
<source/>Am. J. Physiol. Lung Cell. Mol. Physiol.
          <year>2004</year>
<volume>287</volume>
<fpage>L774</fpage>
<lpage>L783</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00110.2004</pub-id>
<pub-id pub-id-type="pmid">15180920</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-00535">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaumeil</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Sfar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Charrueau</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Administration of resveratrol: What formulation solutions to bioavailability limitations?</article-title>
<source/>J. Control. Release
          <year>2012</year>
<volume>158</volume>
<fpage>182</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1016/j.jconrel.2011.09.083</pub-id>
<pub-id pub-id-type="pmid">21978644</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-00535">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kursvietiene</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Staneviciene</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mongirdiene</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernatoniene</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Multiplicity of effects and health benefits of resveratrol</article-title>
<source/>Medicina
          <year>2016</year>
<volume>52</volume>
<fpage>148</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.medici.2016.03.003</pub-id>
<pub-id pub-id-type="pmid">27496184</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-00535">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabjanowicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Płotka-Wasylka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Namieśnik</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Detection, identification and determination of resveratrol in wine. Problems and challenges</article-title>
<source/>TrAC Trends Anal. Chem.
          <year>2018</year>
<volume>103</volume>
<fpage>21</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.trac.2018.03.006</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-00535">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bostanghadiri</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pormohammad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chirani</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Pouriran</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Erfanimanesh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hashemi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Comprehensive review on the antimicrobial potency of the plant polyphenol Resveratrol</article-title>
<source/>Biomed. Pharmacother.
          <year>2017</year>
<volume>95</volume>
<fpage>1588</fpage>
<lpage>1595</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.084</pub-id>
<pub-id pub-id-type="pmid">28950659</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-00535">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>H.-F.</given-names>
</name>
</person-group>
<article-title>Reciprocal Interactions Between Resveratrol and Gut Microbiota Deepen Our Understanding of Molecular Mechanisms Underlying Its Health Benefits</article-title>
<source/>Trends Food Sci. Technol.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.tifs.2018.09.026</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-00535">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cottart</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Nivet-Antoine</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Laguillier-Morizot</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Beaudeux</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Resveratrol bioavailability and toxicity in humans</article-title>
<source/>Mol. Nutr. Food Res.
          <year>2010</year>
<volume>54</volume>
<fpage>7</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1002/mnfr.200900437</pub-id>
<pub-id pub-id-type="pmid">20013887</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-00535">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Porte</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Voduc</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Seguin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tardiff</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cameron</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects</article-title>
<source/>Clin. Pharmacokinet.
          <year>2010</year>
<volume>49</volume>
<fpage>449</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.2165/11531820-000000000-00000</pub-id>
<pub-id pub-id-type="pmid">20528005</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-00535">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gluckman</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The developmental origins of the metabolic syndrome</article-title>
<source/>Trends Endocrinol. Metab.
          <year>2004</year>
<volume>15</volume>
<fpage>183</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/j.tem.2004.03.002</pub-id>
<pub-id pub-id-type="pmid">15109618</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-00535">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gluckman</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Effect of in utero and early-life conditions on adult health and disease</article-title>
<source/>N. Engl. J. Med.
          <year>2008</year>
<volume>359</volume>
<fpage>61</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra0708473</pub-id>
<pub-id pub-id-type="pmid">18596274</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-00535">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bremer</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Resveratrol use in metabolic syndrome</article-title>
<source/>Metab. Syndr. Relat. Disord.
          <year>2014</year>
<volume>12</volume>
<fpage>493</fpage>
<lpage>495</lpage>
<pub-id pub-id-type="doi">10.1089/met.2014.1505</pub-id>
<pub-id pub-id-type="pmid">25229675</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-00535">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elibol</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kilic</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>High Levels of SIRT1 Expression as a Protective Mechanism Against Disease-Related Conditions</article-title>
<source/>Front. Endocrinol.
          <year>2018</year>
<volume>9</volume>
<fpage>614</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00614</pub-id>
<pub-id pub-id-type="pmid">30374331</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-00535">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bishayee</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis</article-title>
<source/>J. Carcinog.
          <year>2009</year>
<volume>8</volume>
<fpage>9</fpage>
<pub-id pub-id-type="pmid">19465777</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-00535">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diaz-Gerevini</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Repossi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dain</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tarres</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>U.N.</given-names>
</name>
<name>
<surname>Eynard</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Beneficial action of resveratrol: How and why?</article-title>
<source/>Nutrition
          <year>2016</year>
<volume>32</volume>
<fpage>174</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2015.08.017</pub-id>
<pub-id pub-id-type="pmid">26706021</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-00535">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Canto</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The molecular targets of resveratrol</article-title>
<source/>Biochim. Biophys. Acta
          <year>2015</year>
<volume>1852</volume>
<fpage>1114</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.10.005</pub-id>
<pub-id pub-id-type="pmid">25315298</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-00535">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umezawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Higurashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>AMPK: Therapeutic Target for Diabetes and Cancer Prevention</article-title>
<source/>Curr. Pharm. Des.
          <year>2017</year>
<volume>23</volume>
<fpage>3629</fpage>
<lpage>3644</lpage>
<pub-id pub-id-type="doi">10.2174/0929867324666170713150440</pub-id>
<pub-id pub-id-type="pmid">28714409</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-00535">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bullon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marin-Aguilar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Roman-Malo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>AMPK/Mitochondria in Metabolic Diseases</article-title>
<source/>Exp. Suppl.
          <year>2016</year>
<volume>107</volume>
<fpage>129</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="pmid">27812979</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-00535">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cristina Orihuela-Campos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H.-O.</given-names>
</name>
</person-group>
<article-title>Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model</article-title>
<source/>Free Radic. Biol. Med.
          <year>2014</year>
<volume>75</volume>
<fpage>222</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.07.034</pub-id>
<pub-id pub-id-type="pmid">25091897</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-00535">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney</article-title>
<source/>Nutrients
          <year>2018</year>
<volume>10</volume>
<elocation-id>1741</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu10111741</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-00535">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>B.S.</given-names>
</name>
</person-group>
<article-title>The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system</article-title>
<source/>Atherosclerosis
          <year>2018</year>
<volume>270</volume>
<fpage>123</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.01.043</pub-id>
<pub-id pub-id-type="pmid">29407880</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-00535">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaplin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carpene</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mercader</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Resveratrol, Metabolic Syndrome, and Gut Microbiota</article-title>
<source/>Nutrients
          <year>2018</year>
<volume>10</volume>
<elocation-id>1651</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu10111651</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-00535">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Oliveira</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Manayi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Daglia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hajheydari</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view</article-title>
<source/>Biochim. Biophys. Acta (BBA) Gen. Subj.
          <year>2016</year>
<volume>1860</volume>
<fpage>727</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagen.2016.01.017</pub-id>
<pub-id pub-id-type="pmid">26802309</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-00535">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Targeting sirtuin 1 to improve metabolism: All you need is NAD(+)?</article-title>
<source/>Pharm. Rev.
          <year>2012</year>
<volume>64</volume>
<fpage>166</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1124/pr.110.003905</pub-id>
<pub-id pub-id-type="pmid">22106091</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-00535">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palsamy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling</article-title>
<source/>Biochim. Biophys. Acta
          <year>2011</year>
<volume>1812</volume>
<fpage>719</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2011.03.008</pub-id>
<pub-id pub-id-type="pmid">21439372</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-00535">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Sá Coutinho</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pacheco</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Frozza</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>1812</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19061812</pub-id>
<pub-id pub-id-type="pmid">29925765</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-00535">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherniack</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Polyphenols: Planting the seeds of treatment for the metabolic syndrome</article-title>
<source/>Nutrition
          <year>2011</year>
<volume>27</volume>
<fpage>617</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2010.10.013</pub-id>
<pub-id pub-id-type="pmid">21367579</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-00535">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckel</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Zimmet</surname>
<given-names>P.Z.</given-names>
</name>
</person-group>
<article-title>The metabolic syndrome</article-title>
<source/>Lancet
          <year>2005</year>
<volume>365</volume>
<fpage>1415</fpage>
<lpage>1428</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)66378-7</pub-id>
<pub-id pub-id-type="pmid">15836891</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-00535">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sata</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Developmental Origins of Health and Disease (DOHaD) and Epidemiology</article-title>
<source/>Nihon Eiseigaku Zasshi. Jpn. J. Hyg.
          <year>2016</year>
<volume>71</volume>
<fpage>41</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1265/jjh.71.41</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-00535">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nüsken</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dötsch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Nüsken</surname>
<given-names>K.-D.</given-names>
</name>
</person-group>
<article-title>Developmental Programming of Renal Function and Re-Programming Approaches</article-title>
<source/>Front. Pediatr.
          <year>2018</year>
<volume>6</volume>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2018.00036</pub-id>
<pub-id pub-id-type="pmid">29535992</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-00535">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tain</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.-T.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C.-N.</given-names>
</name>
</person-group>
<article-title>Developmental Programming of Adult Disease: Reprogramming by Melatonin?</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>426</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18020426</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-00535">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>2584</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19092584</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-00535">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resveratrol protects against spinal cord injury by activating autophagy and inhibiting apoptosis mediated by the SIRT1/AMPK signaling pathway</article-title>
<source/>Neuroscience
          <year>2017</year>
<volume>348</volume>
<fpage>241</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.02.027</pub-id>
<pub-id pub-id-type="pmid">28238848</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-00535">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Quintela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carpene</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aguirre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Milton-Laskibar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Contreras</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Portillo</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Anti-obesity effects of resveratrol: Comparison between animal models and humans</article-title>
<source/>J. Physiol. Biochem.
          <year>2016</year>
<volume>73</volume>
<fpage>417</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1007/s13105-016-0544-y</pub-id>
<pub-id pub-id-type="pmid">27981508</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-00535">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasinetti</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marambaud</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ferruzzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gregor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Knable</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington’s disease and other neurodegenerative disorders</article-title>
<source/>Exp. Neurol.
          <year>2011</year>
<volume>232</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2011.08.014</pub-id>
<pub-id pub-id-type="pmid">21907197</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-00535">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez-del Villar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Ortiz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martinez-Abundis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Perez-Rubio</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Lizarraga-Valdez</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion</article-title>
<source/>Metab. Syndr. Relat. Disord.
          <year>2014</year>
<volume>12</volume>
<fpage>497</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.1089/met.2014.0082</pub-id>
<pub-id pub-id-type="pmid">25137036</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-00535">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korsholm</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Ornstrup</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months’ Treatment</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>554</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18030554</pub-id>
<pub-id pub-id-type="pmid">28273841</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-00535">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiot</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vinet</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Effects of dietary polyphenols on metabolic syndrome features in humans: A systematic review</article-title>
<source/>Obes. Rev.
          <year>2016</year>
<volume>17</volume>
<fpage>573</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1111/obr.12409</pub-id>
<pub-id pub-id-type="pmid">27079631</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-00535">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabrizi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tamtaji</surname>
<given-names>O.R.</given-names>
</name>
<name>
<surname>Lankarani</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Mirhosseini</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Akbari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dadgostar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Peymani</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Asemi</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials</article-title>
<source/>Food Funct.
          <year>2018</year>
<volume>9</volume>
<fpage>6116</fpage>
<lpage>6128</lpage>
<pub-id pub-id-type="doi">10.1039/C8FO01259H</pub-id>
<pub-id pub-id-type="pmid">30426122</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-00535">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunstad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lhotsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wendell</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Ferrucci</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zonderman</surname>
<given-names>A.B.</given-names>
</name>
</person-group>
<article-title>Longitudinal examination of obesity and cognitive function: Results from the Baltimore longitudinal study of aging</article-title>
<source/>Neuroepidemiology
          <year>2010</year>
<volume>34</volume>
<fpage>222</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1159/000297742</pub-id>
<pub-id pub-id-type="pmid">20299802</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-00535">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujitaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Otani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iwasaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>D.K.</given-names>
</name>
</person-group>
<article-title>Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment</article-title>
<source/>Nutr. Res.
          <year>2011</year>
<volume>31</volume>
<fpage>842</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="doi">10.1016/j.nutres.2011.09.028</pub-id>
<pub-id pub-id-type="pmid">22118755</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-00535">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kjaer</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Ornstrup</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Poulsen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Stodkilde-Jorgensen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jessen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>J.O.L.</given-names>
</name>
<name>
<surname>Richelsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2017</year>
<volume>102</volume>
<fpage>1642</fpage>
<lpage>1651</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2016-2160</pub-id>
<pub-id pub-id-type="pmid">28182820</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-00535">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Silva</surname>
<given-names>I.V.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Rebelo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>J.P.G.</given-names>
</name>
<name>
<surname>Soveral</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Revisiting the metabolic syndrome: The emerging role of aquaglyceroporins</article-title>
<source/>Cell. Mol. Life Sci. CMLS
          <year>2018</year>
<volume>75</volume>
<fpage>1973</fpage>
<lpage>1988</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-018-2781-4</pub-id>
<pub-id pub-id-type="pmid">29464285</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-00535">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity</article-title>
<source/>Food Funct.
          <year>2014</year>
<volume>5</volume>
<fpage>1241</fpage>
<lpage>1249</lpage>
<pub-id pub-id-type="doi">10.1039/c3fo60630a</pub-id>
<pub-id pub-id-type="pmid">24722352</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-00535">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorentini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zambonin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dalla Sega</surname>
<given-names>F.V.</given-names>
</name>
<name>
<surname>Hrelia</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Polyphenols as Modulators of Aquaporin Family in Health and Disease</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2015</year>
<volume>2015</volume>
<fpage>196914</fpage>
<pub-id pub-id-type="doi">10.1155/2015/196914</pub-id>
<pub-id pub-id-type="pmid">26346093</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-00535">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cournot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marquié</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ansiau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martinaud</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fonds</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferrières</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ruidavets</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Relation between body mass index and cognitive function in healthy middle-aged men and women</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<fpage>1208</fpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000238082.13860.50</pub-id>
<pub-id pub-id-type="pmid">17030754</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-00535">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>H.I.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Diabetes and Alzheimer’s Disease: Mechanisms and Nutritional Aspects</article-title>
<source/>Clin. Nutr. Res.
          <year>2018</year>
<volume>7</volume>
<fpage>229</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.7762/cnr.2018.7.4.229</pub-id>
<pub-id pub-id-type="pmid">30406052</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-00535">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heyward</surname>
<given-names>F.D.</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gavin</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kaas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Trieu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moulden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sweatt</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Obesity Weighs down Memory through a Mechanism Involving the Neuroepigenetic Dysregulation of Sirt1</article-title>
<source/>J. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>1324</fpage>
<lpage>1335</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1934-15.2016</pub-id>
<pub-id pub-id-type="pmid">26818519</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-00535">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Resveratrol Improves Cognitive Impairment by Regulating Apoptosis and Synaptic Plasticity in Streptozotocin-Induced Diabetic Rats</article-title>
<source/>Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.
          <year>2016</year>
<volume>40</volume>
<fpage>1670</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="doi">10.1159/000453216</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-00535">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Sheen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Tiao</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.T.</given-names>
</name>
</person-group>
<article-title>A maternal high-fat diet during pregnancy and lactation, in addition to a postnatal high-fat diet, leads to metabolic syndrome with spatial learning and memory deficits: Beneficial effects of resveratrol</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>111998</fpage>
<lpage>112013</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.22960</pub-id>
<pub-id pub-id-type="pmid">29340106</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-00535">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Tiao</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.T.</given-names>
</name>
</person-group>
<article-title>Combined maternal and postnatal high-fat diet leads to metabolic syndrome and is effectively reversed by resveratrol: A multiple-organ study</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>5607</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-24010-0</pub-id>
<pub-id pub-id-type="pmid">29618822</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-00535">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robich</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Osipov</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nezafat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Clements</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Sellke</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia</article-title>
<source/>Eur. J. Pharmacol.
          <year>2011</year>
<volume>664</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2011.04.059</pub-id>
<pub-id pub-id-type="pmid">21575630</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-00535">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulsen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>J.O.</given-names>
</name>
<name>
<surname>Hamilton-Dutoit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clasen</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Jessen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Kjaer</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Richelsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet</article-title>
<source/>Nutr. Res.
          <year>2012</year>
<volume>32</volume>
<fpage>701</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="doi">10.1016/j.nutres.2012.08.004</pub-id>
<pub-id pub-id-type="pmid">23084643</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-00535">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Sheen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Resveratrol prevents the combined maternal plus postweaning high-fat-diets-induced hypertension in male offspring</article-title>
<source/>J. Nutr. Biochem.
          <year>2017</year>
<volume>48</volume>
<fpage>120</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2017.06.007</pub-id>
<pub-id pub-id-type="pmid">28825991</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-00535">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szkudelski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Szkudelska</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Resveratrol and diabetes: From animal to human studies</article-title>
<source/>Biochim. Biophys. Acta
          <year>2015</year>
<volume>1852</volume>
<fpage>1145</fpage>
<lpage>1154</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.10.013</pub-id>
<pub-id pub-id-type="pmid">25445538</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-00535">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Resveratrol mitigate structural changes and hepatic stellate cell activation in N′-nitrosodimethylamine-induced liver fibrosis via restraining oxidative damage</article-title>
<source/>Chem. -Biol. Interact.
          <year>2014</year>
<volume>221</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbi.2014.07.007</pub-id>
<pub-id pub-id-type="pmid">25064540</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-00535">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz Demirtas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bircan</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Pasaoglu</surname>
<given-names>O.T.</given-names>
</name>
<name>
<surname>Turkozkan</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The effects of resveratrol on hepatic oxidative stress in metabolic syndrome model induced by high fructose diet</article-title>
<source/>Bratisl. Lek. Listy
          <year>2018</year>
<volume>119</volume>
<fpage>36</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.4149/BLL_2018_008</pub-id>
<pub-id pub-id-type="pmid">29405729</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-00535">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagul</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Middela</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matapally</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Padiya</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bastia</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Madhusudana</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats</article-title>
<source/>Pharm. Res
          <year>2012</year>
<volume>66</volume>
<fpage>260</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2012.05.003</pub-id>
<pub-id pub-id-type="pmid">22627169</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-00535">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Robich</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sellke</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle</article-title>
<source/>Arch. Surg.
          <year>2011</year>
<volume>146</volume>
<fpage>556</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1001/archsurg.2011.100</pub-id>
<pub-id pub-id-type="pmid">21739664</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-00535">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiao</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Sheen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system</article-title>
<source/>Lipids Health Dis.
          <year>2018</year>
<volume>17</volume>
<fpage>178</fpage>
<pub-id pub-id-type="doi">10.1186/s12944-018-0824-3</pub-id>
<pub-id pub-id-type="pmid">30055626</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-00535">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>B.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice</article-title>
<source/>Diabetologia
          <year>2013</year>
<volume>56</volume>
<fpage>204</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-012-2747-2</pub-id>
<pub-id pub-id-type="pmid">23090186</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-00535">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice</article-title>
<source/>Hypertens. Res.
          <year>2014</year>
<volume>37</volume>
<fpage>803</fpage>
<pub-id pub-id-type="doi">10.1038/hr.2014.90</pub-id>
<pub-id pub-id-type="pmid">24965170</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-00535">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oakhill</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>Adipose tissue as an endocrine organ</article-title>
<source/>Mol. Cell. Endocrinol.
          <year>2010</year>
<volume>316</volume>
<fpage>129</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.mce.2009.08.018</pub-id>
<pub-id pub-id-type="pmid">19723556</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-00535">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>M.G.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Leibel</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Obesity and leptin resistance: Distinguishing cause from effect</article-title>
<source/>Trends Endocrinol. Metab. TEM
          <year>2010</year>
<volume>21</volume>
<fpage>643</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1016/j.tem.2010.08.002</pub-id>
<pub-id pub-id-type="pmid">20846876</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-00535">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Dias-Rocha</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Albuquerque Maia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lisboa</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Pazos-Moura</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Trevenzoli</surname>
<given-names>I.H.</given-names>
</name>
</person-group>
<article-title>Resveratrol treatment rescues hyperleptinemia and improves hypothalamic leptin signaling programmed by maternal high-fat diet in rats</article-title>
<source/>Eur. J. Nutr.
          <year>2016</year>
<volume>55</volume>
<fpage>601</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1007/s00394-015-0880-7</pub-id>
<pub-id pub-id-type="pmid">25801629</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-00535">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguirre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fernandez-Quintela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Portillo</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Resveratrol: Anti-obesity mechanisms of action</article-title>
<source/>Molecules
          <year>2014</year>
<volume>19</volume>
<fpage>18632</fpage>
<lpage>18655</lpage>
<pub-id pub-id-type="doi">10.3390/molecules191118632</pub-id>
<pub-id pub-id-type="pmid">25405284</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-00535">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Quintela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milton-Laskibar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Portillo</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Antiobesity effects of resveratrol: Which tissues are involved?</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2017</year>
<volume>1403</volume>
<fpage>118</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1111/nyas.13413</pub-id>
<pub-id pub-id-type="pmid">28796895</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-00535">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagotta</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dimova</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Funcke</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Wabitsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kietzmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fischer-Posovszky</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2013</year>
<volume>2013</volume>
<fpage>793525</fpage>
<pub-id pub-id-type="pmid">23819014</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-00535">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer-Posovszky</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kukulus</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tews</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Unterkircher</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Debatin</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Fulda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wabitsch</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2010</year>
<volume>92</volume>
<fpage>5</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.2009.28435</pub-id>
<pub-id pub-id-type="pmid">20463039</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-00535">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice</article-title>
<source/>PeerJ
          <year>2018</year>
<volume>6</volume>
<fpage>e5173</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.5173</pub-id>
<pub-id pub-id-type="pmid">29967759</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-00535">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kornicka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Szlapka-Kosarzewska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smieszek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marycz</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>5-Azacytydine and resveratrol reverse senescence and ageing of adipose stem cells via modulation of mitochondrial dynamics and autophagy</article-title>
<source/>J. Cell. Mol. Med.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1111/jcmm.13914</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-00535">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peredo-Escarcega</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Guarner-Lans</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Perez-Torres</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ortega-Ocampo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carreon-Torres</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castrejon-Tellez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Diaz-Diaz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rubio-Ruiz</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>The Combination of Resveratrol and Quercetin Attenuates Metabolic Syndrome in Rats by Modifying the Serum Fatty Acid Composition and by Upregulating SIRT 1 and SIRT 2 Expression in White Adipose Tissue</article-title>
<source/>Evid. Based Complement. Altern. Med.
          <year>2015</year>
<volume>2015</volume>
<fpage>474032</fpage>
<pub-id pub-id-type="doi">10.1155/2015/474032</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-00535">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bird</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Raederstorff</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Steinert</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Cardiovascular and Antiobesity Effects of Resveratrol Mediated through the Gut Microbiota</article-title>
<source/>Adv. Nutr.
          <year>2017</year>
<volume>8</volume>
<fpage>839</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="doi">10.3945/an.117.016568</pub-id>
<pub-id pub-id-type="pmid">29141969</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-00535">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silvester</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Aseer</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Dietary polyphenols and their roles in fat browning</article-title>
<source/>J. Nutr. Biochem.
          <year>2018</year>
<volume>64</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2018.09.028</pub-id>
<pub-id pub-id-type="pmid">30414469</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-00535">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Tain</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Tiao</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Sheen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>K.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prenatal dexamethasone and postnatal high-fat diet have a synergistic effect of elevating blood pressure through a distinct programming mechanism of systemic and adipose renin-angiotensin systems</article-title>
<source/>Lipids Health Dis.
          <year>2018</year>
<volume>17</volume>
<fpage>50</fpage>
<pub-id pub-id-type="doi">10.1186/s12944-018-0701-0</pub-id>
<pub-id pub-id-type="pmid">29540174</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-00535">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suganami</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Adipose tissue macrophages: Their role in adipose tissue remodeling</article-title>
<source/>J. Leukoc. Biol.
          <year>2010</year>
<volume>88</volume>
<fpage>33</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.0210072</pub-id>
<pub-id pub-id-type="pmid">20360405</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-00535">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Resveratrol regulates microglia M1/M2 polarization via PGC-1alpha in conditions of neuroinflammatory injury</article-title>
<source/>Brain Behav. Immun.
          <year>2017</year>
<volume>64</volume>
<fpage>162</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2017.03.003</pub-id>
<pub-id pub-id-type="pmid">28268115</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-00535">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carreras</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.X.</given-names>
</name>
<name>
<surname>Almendros</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peris</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gozal</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Resveratrol attenuates intermittent hypoxia-induced macrophage migration to visceral white adipose tissue and insulin resistance in male mice</article-title>
<source/>Endocrinology
          <year>2015</year>
<volume>156</volume>
<fpage>437</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1210/en.2014-1706</pub-id>
<pub-id pub-id-type="pmid">25406018</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-00535">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.L.</given-names>
</name>
</person-group>
<article-title>The effects of either resveratrol or exercise on macrophage infiltration and switching from M1 to M2 in high fat diet mice</article-title>
<source/>J. Exerc. Nutr. Biochem.
          <year>2015</year>
<volume>19</volume>
<fpage>65</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.5717/jenb.2015.15060203</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-00535">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Effects of resveratrol on the amelioration of insulin resistance in KKAy mice</article-title>
<source/>Can. J. Physiol. Pharmacol.
          <year>2012</year>
<volume>90</volume>
<fpage>237</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1139/y11-123</pub-id>
<pub-id pub-id-type="pmid">22309033</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-00535">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagouge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Argmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gerhart-Hines</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Meziane</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lerin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Daussin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Messadeq</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Milne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha</article-title>
<source/>Cell
          <year>2006</year>
<volume>127</volume>
<fpage>1109</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.11.013</pub-id>
<pub-id pub-id-type="pmid">17112576</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-00535">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabe</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Sadek</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Elmadhun</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Dalal</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Robich</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sellke</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Investigating the Effects of Resveratrol on Chronically Ischemic Myocardium in a Swine Model of Metabolic Syndrome: A Proteomics Analysis</article-title>
<source/>J. Med. Food
          <year>2014</year>
<volume>18</volume>
<fpage>60</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1089/jmf.2014.0036</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-00535">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Samdani</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>N.H.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>I.-S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Resveratrol cross-linked chitosan loaded with phospholipid for controlled release and antioxidant activity</article-title>
<source/>Int. J. Biol. Macromol.
          <year>2016</year>
<volume>93</volume>
<fpage>757</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2016.09.018</pub-id>
<pub-id pub-id-type="pmid">27614196</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-00535">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Improvement of antioxidative activity of resveratrol by elongating conjugated chain: A DFT theoretical study</article-title>
<source/>Comput. Theor. Chem.
          <year>2013</year>
<volume>1019</volume>
<fpage>39</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/j.comptc.2013.06.019</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-00535-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Pathway of resveratrol in plant.</p>
</caption>
<graphic xlink:href="ijms-20-00535-g001"></graphic>
</fig>
<fig id="ijms-20-00535-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>The role of resveratrol in metabolic syndrome.</p>
</caption>
<graphic xlink:href="ijms-20-00535-g002"></graphic>
</fig>
<table-wrap id="ijms-20-00535-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-00535-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Summary of clinical and animal studies of resveratrol in metabolic syndrome.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Aim</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Treatment</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Result</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thirty-four patients who had been treated for MetS and lifestyle-related disease were randomly assigned to group A and B. A: Longevinex was administered for 3 months and then discontinued for 3 months. B: Longevinex was administered between 3 and 6 months. (The patients received 1 capsule of Longevinex containing 100 mg trans resveratrol daily after dinner).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Flow-mediated dilatation significantly increased during the administration of Longevinex but decreased to baseline 3 months after the discontinuation of Longevinex in the group A patients. Conversely, in the group B patients, flow-mediated dilatation remained unchanged for the first 3 months without Longevinex but was significantly increased 3 months after the treatment with Longevinex.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B49-ijms-20-00535">49</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Effects of Resveratrol on the Metabolic Syndrome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Middle-aged community-dwelling men (<italic>n</italic> = 74) with MetS, 66 of whom completed all visits (age, 49.5 ± 0.796 years). Daily oral supplementation with 1000 mg RSV (RSVhigh), 150 mg RSV, or placebo, for 16 weeks.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RSVhigh treatment significantly increased total cholesterol (<italic>p</italic> &lt; 0.002), low-density lipoprotein (LDL) cholesterol (<italic>p</italic> &lt; 0.006), and fructosamine (<italic>p</italic> &lt; 0.013) levels compared with placebo.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B50-ijms-20-00535">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">Animal</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The effects of resveratrol on hepatic oxidative stress in metabolic syndrome model induced by high fructose diet</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Male adult rats were induced by MetS, fructose solution (20% in drinking water). Resveratrol (10 mg/kg/day) was given by oral gavage.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fructose-fed rats displayed statistically significant increases in TOS levels and decrease in PON activity compared to the control group, and prevented the decrease in liver PON activity caused by fructose.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B65-ijms-20-00535">65</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation/antioxidant defense pathways in a rat periodontitis model</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Animals in the periodontitis group underwent ligature-induced periodontitis and were given pure water. The melinjo resveratrol was administered orally at a dose of 10 mg/kg body weight.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oral administration of melinjo resveratrol may prevent the progression of ligature-induced periodontitis and improve systemic oxidative and nitrosative stress.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B27-ijms-20-00535">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The Combination of Resveratrol and Quercetin Attenuates Metabolic Syndrome in Rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Each group of rats (control or MetS) received orally in drinking water or sucrose solution a mixture of RSV and QRC daily for 4 week. (1) RSV (10 mg/kg/day) + QRC (0.19 mg/Kg/day). (2) RSV (50 mg/kg/day) + QRC (0.95 mg/kg/day).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RSV + QRC administration improved the serum health parameters modified by MetS and upregulate SIRT 1 and SIRT 2 expression in white abdominal tissue in MetS animals.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B80-ijms-20-00535">80</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fructose-fed insulin resistant group (Dia) animals were fed 65% fructose for a period of 8 weeks, whereas control group animals were fed 65% cornstarch. Resveratrol, 10 mg/kg/day (Dia+Resv) or metformin 300 mg/kg/day (Dia+Met) were administered orally to the 65% fructose-fed rats.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Attenuation of hepatic oxidative stress in fructose-fed rat liver after resveratrol administration was associated with significant increase in the nuclear level of NRF2, and more effective than metformin in improving insulin sensitivity and attenuating metabolic syndrome and hepatic oxidative stress in fructose-fed rats.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B66-ijms-20-00535">66</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A high-fat diet, leads to metabolic syndrome with spatial learning and memory deficits: beneficial effects of resveratrol</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Receive high-fat hypercaloric diet. A therapeutic group with resveratrol on maternal high-fat diet/postnatal high-fat diet was raised for comparison (HHR). 50 mg/kg/day, for 16 weeks.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Treatment with resveratrol is able to rescue that maternal obesity/high-fat diet interacts with a postnatal high-fat diet to induce features of metabolic syndrome include alter biochemical profiles in the dorsal hippocampus, and lead to cognitive deficits.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B58-ijms-20-00535">58</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Combined maternal and postnatal high-fat diet leads to metabolic syndrome and is effectively reversed by resveratrol: a multiple-organ study</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Receive high-fat hypercaloric diet. Resveratrol 50 mg/kg/day, for 16 weeks.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Resveratrol ameliorated most of the features of metabolic syndrome and molecular alterations.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B59-ijms-20-00535">59</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Receive high-fat hypercaloric diet. Resveratrol 50 mg/kg/day for offspring from post-weaning to postnatal day (PND) 120.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Resveratrol administration mediated a protective effect on rats on HF/HF by regulating lipid metabolism, reducing oxidative stress and apoptosis, restoring nutrient-sensing pathways by increasing Sirt1 and leptin expression, and mediating the renin-angiotensin system (RAS) to decrease angiotensinogen, renin, ACE1, and AT1R levels and increased ACE2, AT2R and MAS1 levels compared to those in the OHF group.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B68-ijms-20-00535">68</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The swine developed metabolic syndrome by consuming a high-calorie, high–fat/cholesterol diet for 11 weeks. A hypercholesterolemic group diet with supplemental resveratrol (100 mg/kg/day).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Immunoblotting in the liver showed increased levels of mammalian target of rapamycin, insulin receptor substrate 1, and phosphorylated AKT in the HCRV group. Immunoblotting in skeletal muscle tissue demonstrated increased glucose transporter type 4 (Glut 4), peroxisome proliferating activation receptor coactivator 1α, peroxisome proliferator-activated receptor α, peroxisome proliferator-activated receptor, and phosphorylated AKT at threonine 308 expression as well as decreased retinol binding protein 4 in the HCRV group.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-ijms-20-00535">67</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Investigating the Effects of Resveratrol on Chronically Ischemic Myocardium in a Swine Model of Metabolic Syndrome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The high-cholesterol diet, experimental group were supplemented with daily oral resveratrol (HCRV; 100 mg/kg/day, <italic>n</italic> = 6) for 11 weeks.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">In a swine model with metabolic syndrome and chronic myocardial ischemia, we demonstrate that resveratrol supplementation significantly alters the levels of several key proteins involved in metabolism, cell death, and structural remodeling and decreases myocardial fibrosis.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-ijms-20-00535">90</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>